Logo image of ATLN

ATLANTIC INTERNATIONAL CORP (ATLN) Stock Fundamental Analysis

NASDAQ:ATLN - Nasdaq - US0485921094 - Common Stock - Currency: USD

3.13  -0.1 (-3.1%)

After market: 3.13 0 (0%)

Fundamental Rating

0

ATLN gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. ATLN may be in some trouble as it scores bad on both profitability and health. ATLN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ATLN has reported negative net income.
ATLN had a negative operating cash flow in the past year.
In the past 5 years ATLN always reported negative net income.
In the past 5 years ATLN always reported negative operating cash flow.
ATLN Yearly Net Income VS EBIT VS OCF VS FCFATLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -1M -2M -3M -4M -5M

1.2 Ratios

The Return On Assets of ATLN (-50.18%) is worse than 89.47% of its industry peers.
Looking at the Return On Equity, with a value of -419.55%, ATLN is doing worse than 91.23% of the companies in the same industry.
Industry RankSector Rank
ROA -50.18%
ROE -419.55%
ROIC N/A
ROA(3y)-70%
ROA(5y)-127.94%
ROE(3y)-355.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATLN Yearly ROA, ROE, ROICATLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500

1.3 Margins

ATLN has a worse Gross Margin (10.81%) than 85.96% of its industry peers.
ATLN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATLN Yearly Profit, Operating, Gross MarginsATLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K -5K

More info and screens

1

2. Health

2.1 Basic Checks

ATLN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ATLN has more shares outstanding
ATLN has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, ATLN has a worse debt to assets ratio.
ATLN Yearly Shares OutstandingATLN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
ATLN Yearly Total Debt VS Total AssetsATLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

ATLN has an Altman-Z score of 1.95. This is not the best score and indicates that ATLN is in the grey zone with still only limited risk for bankruptcy at the moment.
ATLN has a Altman-Z score (1.95) which is comparable to the rest of the industry.
A Debt/Equity ratio of 2.26 is on the high side and indicates that ATLN has dependencies on debt financing.
ATLN has a Debt to Equity ratio of 2.26. This is amonst the worse of the industry: ATLN underperforms 87.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.26
Debt/FCF N/A
Altman-Z 1.95
ROIC/WACCN/A
WACC11.55%
ATLN Yearly LT Debt VS Equity VS FCFATLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M 6M 8M

2.3 Liquidity

ATLN has a Current Ratio of 0.91. This is a bad value and indicates that ATLN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.91, ATLN is not doing good in the industry: 91.23% of the companies in the same industry are doing better.
ATLN has a Quick Ratio of 0.91. This is a bad value and indicates that ATLN is not financially healthy enough and could expect problems in meeting its short term obligations.
ATLN has a worse Quick ratio (0.91) than 84.21% of its industry peers.
Industry RankSector Rank
Current Ratio 0.91
Quick Ratio 0.91
ATLN Yearly Current Assets VS Current LiabilitesATLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.07% over the past year.
ATLN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)67.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.26%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ATLN will show a very negative growth in Earnings Per Share. The EPS will decrease by -13.23% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-64.1%
EPS Next 2Y-13.23%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATLN Yearly Revenue VS EstimatesATLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
ATLN Yearly EPS VS EstimatesATLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATLN. In the last year negative earnings were reported.
Also next year ATLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATLN Price Earnings VS Forward Price EarningsATLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATLN Per share dataATLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A cheap valuation may be justified as ATLN's earnings are expected to decrease with -13.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.23%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ATLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATLANTIC INTERNATIONAL CORP

NASDAQ:ATLN (2/12/2025, 8:00:00 PM)

After market: 3.13 0 (0%)

3.13

-0.1 (-3.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners18.06%
Ins Owner Change8.97%
Market Cap156.97M
Analysts82.86
Price TargetN/A
Short Float %0.02%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.5
P/FCF N/A
P/OCF N/A
P/B 9.67
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.55
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS6.24
BVpS0.32
TBVpS-0.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.18%
ROE -419.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.81%
FCFM N/A
ROA(3y)-70%
ROA(5y)-127.94%
ROE(3y)-355.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover2.31
Health
Industry RankSector Rank
Debt/Equity 2.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.33%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.91
Quick Ratio 0.91
Altman-Z 1.95
F-Score3
WACC11.55%
ROIC/WACCN/A
Cap/Depr(3y)34.15%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.26%
EPS Next Y-64.1%
EPS Next 2Y-13.23%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-199.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-69.53%
OCF growth 3YN/A
OCF growth 5YN/A